eISSN: 2300-6722
ISSN: 1899-1874
Medical Studies/Studia Medyczne
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2023
vol. 39
 
Share:
Send email
Share:
abstract:
Original paper

Relationship between expression of blood circulating lncRNA: LRRC75A-AS1, clinical characteristics and prognosis of chronic heart failure patients

Agata Kot
1
,
Aneta Skwarek-Dziekanowska
2
,
Grzegorz Sobieszek
2
,
Teresa Małecka-Massalska
3
,
Tomasz Powrózek
3

  1. Care and Treatment Facility, Cardinal Wyszynski Voivodeship Specialist Hospital, Lublin, Poland
  2. Department of Cardiology, 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland
  3. Department of Human Physiology of the Chair of Preclinical Sciences, Medical University in Lublin, Lublin, Poland
Medical Studies/Studia Medyczne 2023; 39 (3): 215–222
DOI: https://doi.org/10.5114/ms.2023.131687
Online publish date: 2023/09/30
View full text Get citation
 
PlumX metrics:
Introduction
A complex interplay of genetics and multiple biological mechanisms contributes not only to chronic heart failure (CHF) progression and an unfavorable prognosis, but also makes biomarker selection difficult. Discovery of novel molecular markers, such as lncRNAs, has provided a new approach to biomarker study, including for CHF.

Aim of the research
In this study, we focused on blood circulating LRRC75A-AS1 as a novel prospective biomarker reflecting the clinical image and prognosis of CHF patients.

Material and methods
The lncRNA expression was examined in plasma samples of 108 newly diagnosed CHF patients and correlated with clinical outcomes.

Results
Low expression of LRRC75A-AS1 was associated with a greater inflammatory response reflected by higher plasma concentrations of C-reactive protein, interleukin-6 and tumor necrosis factor . Patients with low lncRNA expression had lower serum albumin concentration and they were more frequently classified as NYHA grade III or IV, had PASP ≥ 36 mm Hg and more often demonstrated presence of exertional dyspnea. The Cox regression model selected downexpression of LRRC75A-AS1 as an independent prognostic factor related to poor survival of CHF (HR = 2.17).

Conclusions
Blood circulating LRRC75A-AS1 seems to be an attractive biomarker supporting clinical assessment of CHF patients. Expression of the lncRNA reflects the extent of the CHF symptoms and severity of the systemic inflammatory response, which can be useful for selection of patients with an unfavorable disease course and higher risk of death.

keywords:

chronic heart failure, lncRNA, LRRC75A-AS1, biomarker
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.